海天精工(601882.SH):部分董監高已減持191.36萬股
格隆匯11月19日丨海天精工(601882.SH)公佈,2021年11月19日,公司收到董事兼副總經理趙萬勇、監事會主席童永紅、副總經理俞鴻剛分別出具的《關於減持公司股份計劃實施完畢的吿知函》。
截至公吿披露日,趙萬勇通過集中競價交易方式累積減持公司股份73.6萬股,佔公司總股本的0.14%;童永紅通過集中競價交易方式累積減持公司股份66.24萬股,佔公司總股本的0.13%;俞鴻剛通過集中競價交易方式累積減持公司股份51.52萬股,佔公司總股本的0.10%。趙萬勇、童永紅、俞鴻剛的此次減持計劃已實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.